FDA advisory committee votes to recommend BPC-157, TB-500, MOTS-c, Epithalon, and Semax for the 503A compounding bulks list
The FDA's Pharmacy Compounding Advisory Committee voted across July 23–24, 2026 on whether seven research peptides should be added to the list governing what compounding pharmacies may legally prepare. Six of seven — including BPC-157, TB-500, MOTS-c, Epithalon, and Semax — received recommending votes, overriding the agency's own staff review, which had argued the safety and effectiveness data was insufficient. The vote is non-binding; a final FDA rulemaking decision is still pending.
This is a summary. The reporting is U.S. Food & Drug Administration's, and the link below goes to the original article.